HyperBranch receives CE Mark
Durham, N.C (July 21, 2009) — HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its NuSeal 100 dural sealant product. NuSeal 100 is used in cranial neurosurgical procedures where a water tight seal is required on the dura. NuSeal 100 is intended for direct application on the dural surfaces to provide a positive seal after suturing thereby minimizing risks associated with post-surgical CSF leaks. The CE Mark for NuSeal 100 provides regulatory approval for the company to begin sales in Europe and potentially other countries outside the U.S.
The unique, single use device is terminally sterilized and sets on contact after a spray application. The synthetic, biocompatible composition is stored at room temperature and is delivered through the custom applicator to meet the specific needs of the procedure. The intended users of NuSeal 100 are Neurosurgeons in a surgical environment.
John Conn President and CEO said: "NuSeal 100 is a significant improvement in surgical sealants; it is long lasting, strong, has low swelling and is safely eliminated from the body. NuSeal 100 is our second product and represents a major technology enhancement which will provide a platform for the development of several other indications for use".
The Durham, N.C. medical device company has also been developing advanced surgical sealants for pleural (lung), cardiovascular and hernia mesh fixation. These products are at various stages of clinical and pre-clinical development. The company also has licensed its ophthalmic sealant to BD Medical for sale outside the United States.
About HyperBranch Medical Technology, Inc.
HyperBranch Medical Technology, a privately-held company based in Durham, N.C., is developing innovative medical devices for the ophthalmology, general, and specialty surgery markets. The company is focused on the development of unique products based on its novel hydrogel technology. Development work on HyperBranch’s surgical sealant platform has led to the recognition of several novel hydrogel properties that suggest significant utility in a variety of additional clinical applications for more information visit www.hyperbranch.com..